Q-RNA Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$11M
Q-RNA General Information
Description
Provider of biotechnology. The company engages in discovery and development of RNA ligands, specialized RNA molecules that bind and functionally interact with desired targets. They can be used to detect the presence (or absence) of virtually any organic or inorganic target with extreme sensitivity and specificity and have applications in medicinal diagnosis and the treatment of disorders and diseases. The company is currently focused on diseases such as Alzheimer's, epilepsy and Parkinson's disease.
Contact Information
Website
www.q-rna.comCorporate Office
- 3960 Broadway
- Suite 407
- New York, NY 10032
- United States
Corporate Office
- 3960 Broadway
- Suite 407
- New York, NY 10032
- United States
Q-RNA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 17-Nov-2006 | $11M | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series B) | 02-Jun-2003 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 08-Aug-2001 | $700K | $700K | Completed | Generating Revenue |
Q-RNA Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Q-RNA Patents
Q-RNA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2006116272-A1 | Compositions and methods for binding agglomeration proteins | Inactive | 22-Apr-2005 | ||
| WO-2006110449-A2 | Agglomeration protein cascades, compositions and methods regarding the same | Inactive | 07-Apr-2005 | ||
| WO-2006110449-A3 | Agglomeration protein cascades, compositions and methods regarding the same | Inactive | 07-Apr-2005 | ||
| WO-2006076296-A2 | A non-naturally occurring animal that expresses an untranslated non-coding rna | Inactive | 10-Jan-2005 | ||
| WO-2006076296-A3 | A non-naturally occurring animal that expresses an untranslated non-coding rna | Inactive | 10-Jan-2005 | A01K67/68 |
Q-RNA Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Double D Venture | Venture Capital | Minority | ||
| Durand Venture Associates | Venture Capital | Minority | ||
| Wheatley Partners | PE/Buyout | Minority |
Q-RNA FAQs
-
When was Q-RNA founded?
Q-RNA was founded in 1996.
-
Where is Q-RNA headquartered?
Q-RNA is headquartered in New York, NY.
-
What industry is Q-RNA in?
Q-RNA’s primary industry is Biotechnology.
-
Is Q-RNA a private or public company?
Q-RNA is a Private company.
-
What is the current valuation of Q-RNA?
The current valuation of Q-RNA is .
-
What is Q-RNA’s current revenue?
The current revenue for Q-RNA is .
-
How much funding has Q-RNA raised over time?
Q-RNA has raised $3.3M.
-
Who are Q-RNA’s investors?
Double D Venture, Durand Venture Associates, and Wheatley Partners have invested in Q-RNA.
-
When was Q-RNA acquired?
Q-RNA was acquired on 17-Nov-2006.
-
Who acquired Q-RNA?
Q-RNA was acquired by Neuro-Hitech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process